Imperial College London

DrEdwardCurry

Faculty of MedicineDepartment of Surgery & Cancer

Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2125e.curry

 
 
//

Location

 

Open PlanInstitute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Summary

Ed Curry leads the Bioinformatics Hub in the Division of Cancer at Imperial College. His research group works on the analysis of datasets from a wide range of platforms profiling the genetic, epigenetic and transcriptional state of cells during cancer development and acquisition of drug resistance. One aspect of this work involves development of methodology for the sophisticated integration of multiple molecular datasets.

Another area of Ed's bioinformatics work focuses on identifying biologically informative patterns that exist within subsets of large, heterogeneous datasets. This is particularly important when studying cancers, as mechanisms of carcinogenesis and drug resistance are rarely conserved across across all patients with a particular disease, or indeed even across all cells from an individual tumour.

Ed is senior tutor for the Cancer Informatics MRes programme, and lectures on courses across the Faculty of Medicine.

Software:

Publications

Journals

Janczar S, Nautiyal J, Xiao Y, et al., 2017, WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response, Cell Death & Disease, Vol:8, ISSN:2041-4889

Simmonds P, Loomis E, Curry E, 2017, DNA methylation-based chromatin compartments and ChIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis, Genome Medicine, Vol:9

Tomaz RA, Harman JL, Karimlou D, et al., 2017, Jmjd2c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation, Development, Vol:144, ISSN:0950-1991, Pages:567-579

Cheraghchi-Bashi A, Parker CA, Curry E, et al., 2015, A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway, Oncotarget, Vol:6, ISSN:1949-2553, Pages:41736-41749

Curry E, Green I, Chapman-Rothe N, et al., 2015, Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells, Clinical Epigenetics, Vol:7, ISSN:1868-7083

More Publications